Livogrit at concentration of 30 μg/mL was able to prevent NASH development by decreasing lipid accumulation, ROS production, AST release, NFκB activation and increasing lipolysis, GSH (reduced glutathione), and mitochondrial membrane potential. This evidence concerns the gene NFKB1 and metabolic dysfunction-associated steatohepatitis.